Semaglutide 2.4mg Pen Injection

Semaglutide 2.4mg Pen Injection is a prescription once-weekly GLP-1 receptor agonist injection containing semaglutide 2.4mg for subcutaneous administration. The 2.4mg strength is an established higher-dose semaglutide injection strength and is the recommended maintenance dose of Wegovy® for many eligible adults receiving treatment for chronic weight management. Current U.S. prescribing information lists a 2.4mg dose delivered by a single-dose prefilled pen.

Semaglutide works by activating GLP-1 receptors involved in appetite regulation, food intake and glucose metabolism. For approved weight-management indications, it is used together with a reduced-calorie diet and increased physical activity.

Product Information

Generic Name

Semaglutide

Strength

2.4mg

Dosage Form

Pen Injection

Common Reference Concentration

2.4mg/0.75mL

Route

Subcutaneous

Drug Class

GLP-1 Receptor Agonist

Therapeutic Class

GLP-1 / Anti-obesity Medicine

Active Ingredient

Semaglutide

Administration

Once Weekly, When Prescribed

Reference Brand

Wegovy®

Prescription

Yes

Packing

Manufacturer Dependent

Manufacturer

Product/Brand Dependent

What Is Semaglutide 2.4mg Pen Injection?

Semaglutide 2.4mg Pen Injection contains 2.4mg of semaglutide in a prefilled injection pen intended for subcutaneous administration.

The 2.4mg strength is specifically established for Wegovy® injection. Current U.S. prescribing information identifies 2.4mg as the recommended maintenance dosage for eligible adults using Wegovy for chronic weight management.

Semaglutide 2.4mg is generally reached through gradual dose escalation rather than being used as the initial dose.

Semaglutide 2.4mg Pen vs Wegovy 2.4mg

Wegovy® is the reference branded semaglutide injection associated with the 2.4mg maintenance strength.

A Semaglutide 2.4mg Pen manufactured by another pharmaceutical company may contain the same active ingredient and strength, but the manufacturer, formulation, injection device, packaging and regulatory authorization may differ.

Where legally authorized, commercially relevant search relationships include:

Semaglutide 2.4mg → Semaglutide 2.4mg Injection → Generic Semaglutide 2.4mg → Generic Wegovy 2.4mg → Wegovy 2.4mg Alternative

Generic Semaglutide 2.4mg

Generic Semaglutide 2.4mg refers to a semaglutide product manufactured and marketed by a company other than the reference-brand manufacturer where such generic or equivalent marketing is legally authorized.

Relevant commercial search terms include:

• Generic Semaglutide 2.4mg
• Generic Semaglutide 2.4mg Injection
• Generic Semaglutide 2.4mg Pen
• Generic Semaglutide Injection
• Generic Semaglutide Pen
• Generic Wegovy 2.4mg
• Wegovy 2.4mg Alternative
• Semaglutide 2.4mg Alternative

Semaglutide 2.4mg and Ozempic

Ozempic® is another branded semaglutide injection, primarily approved for specific type 2 diabetes indications.

Although both Ozempic and Wegovy contain semaglutide, they are different branded products with different approved indications and dosing regimens.

The 2.4mg dose is associated with Wegovy's approved weight-management dosing rather than standard Ozempic dosing.

Availability & Ordering

Semaglutide 2.4mg Pen Injection is a prescription medicine and availability varies by country, manufacturer and regulatory authorization.

Customers searching for Semaglutide 2.4mg Pen Injection, Semaglutide 2.4mg Injection, Generic Semaglutide 2.4mg, Buy Semaglutide 2.4mg, Semaglutide 2.4mg Price, Generic Wegovy 2.4mg, Wegovy 2.4mg Alternative and related commercial terms can check availability through appropriately licensed pharmacies and pharmaceutical suppliers.

Prescription, dispensing, shipping and importation requirements differ across the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.

How it works

Semaglutide is a GLP-1 receptor agonist that activates GLP-1 receptors involved in appetite, food intake and glucose regulation.

It can:

• Increase insulin secretion when blood glucose is elevated
• Reduce glucagon secretion
• Slow gastric emptying
• Reduce appetite and food intake
• Support reduction in excess body weight
• Help maintain weight reduction as part of an appropriate long-term treatment plan

For weight-management treatment, semaglutide is prescribed alongside a reduced-calorie diet and increased physical activity.

Depending on the specific product and regulatory approval, semaglutide injection may be prescribed for:

• Chronic weight management
• Weight loss
• Weight maintenance
• Obesity
• Overweight in adults with weight-related medical conditions
• Cardiovascular risk reduction in eligible patients with established cardiovascular disease
• Other approved indications according to local product labeling

The approved indication should always be confirmed against the specific manufacturer's prescribing information.

Semaglutide treatment is generally titrated gradually to improve tolerability.

For Wegovy, the U.S. dosing schedule begins at 0.25mg once weekly and increases every four weeks through 0.5mg, 1mg and 1.7mg before reaching the recommended maintenance dosage of 2.4mg once weekly for many adults.

The appropriate maintenance dose may vary according to the patient's response and tolerability. Semaglutide 2.4mg should not be used as an initial dose unless specifically directed by a qualified healthcare professional.